VACCINES

Gumboro Disease or Infectious Bursal Disease Virus (IBDV)

Porcine Circovirus 2 (PCV2)
Reproductive and Respiratory Syndrome (PRRS)
Immunocastration

Bovine Viral Diarrhoea Virus (BVDV)
Foot-and-Mouth Disease (FMD)

Gumboro Disease or Infectious Bursal Disease (IBD)

Gumboro is a highly contagious chickens disease caused by the infectious bursal disease virus (IBDV) that provokes a immunosuppression and chicken death at the age of 3 to 6 weeks of life.

It is worldwide distributed and is highly contagious, therefore is responsible of great economic losses in the poultry industry.

VLPbio is developing a vaccine which has demonstrated clinically meaningful and statistically significant protective action after a simple spray administration, despite presence of maternal antibodies and without affecting the bursa. This new vaccine has reduced production costs and has a great potential to be very helpful for the poultry enterprises and farmers.

Gumboro Disease or Infectious Bursal Disease (IBD)

Gumboro is a highly contagious chickens disease caused by the infectious bursal disease virus (IBDV) that provokes a immunosuppression and chicken death at the age of 3 to 6 weeks of life.

It is worldwide distributed and is highly contagious, therefore is responsible of great economic losses in the poultry industry.

VLPbio is developing a vaccine which has demonstrated clinically meaningful and statistically significant protective action after a simple spray administration, despite presence of maternal antibodies and without affecting the bursa. This new vaccine has reduced production costs and has a great potential to be very helpful for the poultry enterprises and farmers.

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)

It is a panzootic disease that causes reproductive failure in breeding stock and respiratory tract illness in young pigs.  Probably is one of the most devastating diseases and causes mayor economic loses in swine industry. The disease costs to the United States swine industry are around $644 million annually, and recently in Europe have been estimated in about 1.5b€ per year.

VLPbio is applying its Ch-VLP technology to develop vaccine prototypes against PRRSV. In vivo tests in pigs are clearly demonstrating the induction of either specific neutralizing or cellular responses to the virus after vaccination.

Porcine Circovirus (PCV 2)

Porcine circovirus type 2 (PCV2) is the causative agent of several pathological conditions in the pig population worldwide known as postweaning multisystemic wasting syndrome (PMWS) which is also associated with porcine dermatitis and nephropathy syndrome (PDNS) as well as other procine reproductive disorders.

This disease has impacted huge economic loss on swine production in all the regions of the globe.

VLPbio’s multi-disciplinary team of experts are leading the immunogenicity and challenge studies on pigs for new vaccine candidates against PCV2. The production process have been already developed with high yields and reduced costs.

Immunocastration Product (TeStop)

Boar taint is a smell that can be detected on meat from sexually mature male pigs which have not been castrated. Many consumers can detect the smell in the meat and is often described as “faecal” or “urine”. Surgical castration (with or without anaesthesia) of piglets is a routine practice in pig production farms to prevent the incidence of boar taint of pig meat.

VLPbio is developing an alternative product for immunocastration that would avoid traumatic castration surgery. This product is nowadays being tested in pigs to demonstrate its efficacy.

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)

It is a panzootic disease that causes reproductive failure in breeding stock and respiratory tract illness in young pigs. Probably is one of the most devastating diseases and causes mayor economic loses in swine industry. The disease costs to the United States swine industry are around $644 million annually, and recently in Europe have been estimated in about 1.5b€ per year.

VLPbio is applying its Ch-VLP technology to develop vaccine prototypes against PRRSV. In vivo tests in pigs are clearly demonstrating the induction of either specific neutralizing or cellular responses to the virus after vaccination.

Porcine Circovirus (PCV 2)

Porcine circovirus type 2 (PCV2) is the causative agent of several pathological conditions in the pig population worldwide known as postweaning multisystemic wasting syndrome (PMWS) which is also associated with porcine dermatitis and nephropathy syndrome (PDNS) as well as other procine reproductive disorders.

This disease has impacted huge economic loss on swine production in all the regions of the globe.

VLPbio’s multi-disciplinary team of experts are leading the immunogenicity and challenge studies on pigs for new vaccine candidates against PCV2. The production process have been already developed with high yields and reduced costs.

Immunocastration Product (TeStop)

Boar taint is a smell that can be detected on meat from sexually mature male pigs which have not been castrated. Many consumers can detect the smell in the meat and is often described as “faecal” or “urine”. Surgical castration (with or without anaesthesia) of piglets is a routine practice in pig production farms to prevent the incidence of boar taint of pig meat.

VLPbio is developing an alternative product for immunocastration that would avoid traumatic castration surgery. This product is nowadays being tested in pigs to demonstrate its efficacy.

Infection of Foot-and-Mouth-Disease (FMD)

Foot-and-mouth disease (FMD) is a transboundary highly contagious virus disease that affects to cloven-hoofed animals, including cattle, buffalo, camels, sheep, goats, deer or pigs. Is one of the most serious livestock diseases because severely affects the production and regional and international trade of animals and animal products. Vaccination can play an important role in an effective control for FMD, but the use of live virus vaccines is not acceptable due to the danger of reversion to virulence.

Nowadays, VLPbio has obtained good results for the new Ch-VLP based vaccine prototypes, with 100% assured biosecurity in murine models. This make us confident for the upcoming test with target cloven-hoofed animals.

Bovine Viral Diarrhoea Virus (BVDV)

Bovine viral diarrhoea is an endemic cattle disease in many countries that generates great economic losses to the cattle industry.

Vaccines directed against BVDV have been available for over 50 years, but still no vaccine is considered to be 100% efficacious.

Some of the unique characteristics of Ch-VLP platform confers them a great potential as an ideal vehicle to generate innovative vaccines against BVDV such us: the ability to boost and direct a specific immune response, the high level of biosecurity and the possibility of unequivocally differentiate infected from vaccinated animals (DIVA vaccines). VLPbio has developed different vaccines prototypes against BVDV that are being tested in target animals.